L-161-2023

Agreement ID
L-161-2023
Lead IC
NIAID
Exclusivity
Nonexclusive
External Party
Maxvax Biotechnology LLC
Fiscal Year
2023
Territory
Other
Execution Date
Effective Date
Export Date
Technologies
TAB-2717     Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine
TAB-3342     Fusion Glycoprotein Vaccine for Human Metapneumovirus
TAB-3336     Substitutions-Modified Prefusion RSV F Proteins and Their Use
TAB-3429     Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus